The preliminary success of a therapy designed to help infants with symptoms of autism raises broader questions about the potential promise and many challenges of early intervention.

On 1 October, Mark Daly discussed new insights into autism from common and rare genetic variants. (Due to technical issues, the video replay for this webinar is unavailable.)

The presenters for this year’s Autism Research Social at SfN have been selected. If you’ll be at conference, please join us 17 November for an evening of food, conversation and new data.

News stories about autism in China are becoming more common, but tend to skimp on scientific facts, reports a study of five leading daily newspapers.

New estimates on the role of common mutations in autism raise questions about how to quantify and parse genetic risk. Three experts say both common and rare variants are worth pursuing.
 

Reports of a century-old drug that reverses autism-like symptoms in mice raise key questions about the complexity of translating promising research into real treatments.

Autism researchers collaborate a great deal, says Helen Tager-Flusberg, and collaboration has increased over the past five years — most likely reflecting the maturation of the field and the greater opportunities to meet.

Watch the complete replay of Robert Malenka’s webinar on the molecular underpinnings of social reward.

Watch the complete replay of Jeremy Veenstra-VanderWeele’s webinar on conceptual pathways for developing effective autism drugs.

If inherited risk for autism is 50 percent, does that make the remaining half of risk environmental? Scientists clarify a large population study.